316 related articles for article (PubMed ID: 31232712)
1. Advances in management of chronic metabolic acidosis in chronic kidney disease.
Chen W; Abramowitz MK
Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):409-416. PubMed ID: 31232712
[TBL] [Abstract][Full Text] [Related]
2. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.
Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
Lancet; 2019 Apr; 393(10179):1417-1427. PubMed ID: 30857647
[TBL] [Abstract][Full Text] [Related]
3. Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial.
Mathur VS; Li E; Wesson DE
Nephrol Dial Transplant; 2022 Jun; 37(7):1302-1309. PubMed ID: 34240198
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease.
Klaerner G; Shao J; Biyani K; Kade M; Kierstead P; Gbur R; Tabakman S; Nguyen S; Buysse J
J Pharmacol Exp Ther; 2020 Dec; 375(3):439-450. PubMed ID: 33033169
[TBL] [Abstract][Full Text] [Related]
5. Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial.
Mathur VS; Wesson DE; Tangri N; Li E; Bushinsky DA
BMC Nephrol; 2022 Feb; 23(1):82. PubMed ID: 35216581
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.
Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
Lancet; 2019 Aug; 394(10196):396-406. PubMed ID: 31248662
[TBL] [Abstract][Full Text] [Related]
7. Effect of Treatment of Metabolic Acidosis on Vascular Endothelial Function in Patients with CKD: A Pilot Randomized Cross-Over Study.
Kendrick J; Shah P; Andrews E; You Z; Nowak K; Pasch A; Chonchol M
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1463-1470. PubMed ID: 30237219
[TBL] [Abstract][Full Text] [Related]
8. Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis.
Mathur VS; Bushinsky DA; Inker L; Klaerner G; Li E; Parsell D; Perkovic V; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Tangri N
Nephrol Dial Transplant; 2023 May; 38(6):1448-1458. PubMed ID: 36331426
[TBL] [Abstract][Full Text] [Related]
9. Approach to the Treatment of Chronic Metabolic Acidosis in CKD.
Raphael KL
Am J Kidney Dis; 2016 Apr; 67(4):696-702. PubMed ID: 26776539
[TBL] [Abstract][Full Text] [Related]
10. Veverimer: An Emerging Potential Treatment Option for Managing the Metabolic Acidosis of CKD.
Adrogué HJ; Madias NE
Am J Kidney Dis; 2020 Dec; 76(6):861-867. PubMed ID: 32920151
[TBL] [Abstract][Full Text] [Related]
11. A basic solution for a complex problem: does treatment of metabolic acidosis slow CKD progression?
Bodker K; Freidin N; Arora N
Curr Opin Nephrol Hypertens; 2024 May; 33(3):304-310. PubMed ID: 38420899
[TBL] [Abstract][Full Text] [Related]
12. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD.
Bushinsky DA; Hostetter T; Klaerner G; Stasiv Y; Lockey C; McNulty S; Lee A; Parsell D; Mathur V; Li E; Buysse J; Alpern R
Clin J Am Soc Nephrol; 2018 Jan; 13(1):26-35. PubMed ID: 29102959
[TBL] [Abstract][Full Text] [Related]
13. Impact of Serum Bicarbonate Levels on Muscle Mass and Kidney Function in Pre-Dialysis Chronic Kidney Disease Patients.
Kittiskulnam P; Srijaruneruang S; Chulakadabba A; Thokanit NS; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
Am J Nephrol; 2020; 51(1):24-34. PubMed ID: 31752000
[TBL] [Abstract][Full Text] [Related]
14. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study.
Di Iorio BR; Bellasi A; Raphael KL; Santoro D; Aucella F; Garofano L; Ceccarelli M; Di Lullo L; Capolongo G; Di Iorio M; Guastaferro P; Capasso G;
J Nephrol; 2019 Dec; 32(6):989-1001. PubMed ID: 31598912
[TBL] [Abstract][Full Text] [Related]
15. Chronic Metabolic Acidosis in Chronic Kidney Disease.
Patschan D; Patschan S; Ritter O
Kidney Blood Press Res; 2020; 45(6):812-822. PubMed ID: 33264780
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Acidosis in CKD: Pathogenesis, Adverse Effects, and Treatment Effects.
Raphael KL
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791238
[TBL] [Abstract][Full Text] [Related]
17. Successful correction of metabolic acidosis is difficult to achieve in chronic kidney disease.
Caravaca-Fontán F; Díaz-Campillejo R; Valladares J; López Arnaldo C; Barroso S; Luna E; Caravaca F
Nefrologia (Engl Ed); 2020; 40(3):328-335. PubMed ID: 31862183
[TBL] [Abstract][Full Text] [Related]
18. Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study).
Gaggl M; Cejka D; Plischke M; Heinze G; Fraunschiel M; Schmidt A; Hörl WH; Sunder-Plassmann G
Trials; 2013 Jul; 14():196. PubMed ID: 23826760
[TBL] [Abstract][Full Text] [Related]
19. Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial.
Dubey AK; Sahoo J; Vairappan B; Haridasan S; Parameswaran S; Priyamvada PS
Nephrol Dial Transplant; 2020 Jan; 35(1):121-129. PubMed ID: 30053298
[TBL] [Abstract][Full Text] [Related]
20. [Sodium bicarbonate to slow the progression of chronic kidney disease].
Rossier A; Bullani R; Burnier M; Teta D
Rev Med Suisse; 2011 Mar; 7(284):478-82. PubMed ID: 21462516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
